This is an important finding as it suggests that DCAF1 and EZH2 inhibitors may be combined to achieve a more favorable therapeutic index for colon cancer patients by establishing distinct epigenetic states at growth regulatory genes. This evidence concerns the gene DCAF1 and colonic neoplasm.